Barclays Increases Insulet (NASDAQ:PODD) Price Target to $234.00

Insulet (NASDAQ:PODD - Get Free Report) had its target price raised by Barclays from $220.00 to $234.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an "equal weight" rating on the medical instruments supplier's stock. Barclays's target price would suggest a potential downside of 15.13% from the company's previous close.

A number of other equities analysts also recently commented on the stock. Raymond James upped their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research note on Monday, October 14th. UBS Group lifted their target price on Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a research report on Friday, August 9th. Citigroup increased their price target on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a research report on Tuesday, October 1st. BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a report on Friday. Finally, Morgan Stanley increased their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $253.27.

Insulet Price Performance

Insulet stock traded up $7.70 during midday trading on Monday, reaching $275.70. 803,320 shares of the stock traded hands, compared to its average volume of 782,225. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet has a 12 month low of $156.00 and a 12 month high of $279.40. The stock's fifty day moving average is $233.46 and its 200-day moving average is $205.26. The stock has a market cap of $19.33 billion, a P/E ratio of 47.21, a PEG ratio of 5.00 and a beta of 1.22.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 21.22% and a return on equity of 30.29%. Insulet's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.38 earnings per share. As a group, equities research analysts anticipate that Insulet will post 3.1 EPS for the current year.

Hedge Funds Weigh In On Insulet

A number of institutional investors have recently modified their holdings of the stock. Diversified Trust Co raised its position in Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier's stock valued at $1,842,000 after acquiring an additional 4,348 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier's stock valued at $1,140,000 after purchasing an additional 3,539 shares during the period. Natixis acquired a new stake in Insulet during the first quarter valued at $3,610,000. Seven Eight Capital LP purchased a new position in Insulet in the first quarter valued at $1,418,000. Finally, Mitsubishi UFJ Trust & Banking Corp raised its position in shares of Insulet by 246.2% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 135,547 shares of the medical instruments supplier's stock worth $23,168,000 after acquiring an additional 96,390 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.